Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

Niemann-Pick Disease Clinical Trial

Official title:

A Phase I, Single-Center, Single Dose, Dose Escalation Study of Recombinant Human Acid Sphingomyelinase (rhASM) in Adults With Acid Sphingomyelinase Deficiency (ASMD)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00410566
• Other study ID #: SPHINGO00605
• Status: Terminated
• Phase: Phase 1
• First received: December 11, 2006
• Last updated: March 17, 2015
• Start date: December 2006
• Est. completion date: April 2009

Study information

• Verified date: March 2015
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safe range of single doses of rhASM administered to adults with ASM deficiency.

Description:

ASM deficiency (ASMD), also known as Niemann-Pick A and B disease, is a rare genetic disorder in which reduced activity of the lysosomal enzyme, ASM, leads to the accumulation of sphingomyelin primarily in macrophages throughout the body. This deficiency results in characteristic features such as hepatosplenomegaly, thrombocytopenia, interstitial lung disease, growth retardation, coronary artery disease, fatigue, and in severe cases, neurodegeneration with death in early childhood. There is no specific treatment for this disease. This Phase 1 safety study will seek to enroll a minimum of 12 and a maximum of 30 eligible adults patients with ASMD with each patient participating for approximately 7 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: April 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Signed, informed consent by the patient or legal guardian prior to performing any study-related procedures;

• Have = 0.2 nmol/hr/mg protein ASM activity in peripheral leukocytes, as measured by the reference laboratory;

• Have a diffusing capacity (DLco) > 30% of the predicted normal value;

• Have a spleen volume = 2x normal

• Female patients of childbearing potential must have a serum pregnancy test negative for ß-hCG and agree to use a reliable birth control method for the duration of the study.

Exclusion Criteria:

• Is pregnant or lactating;

• Has received an investigational drug within 30 days prior to study enrollment;

• Has a medical condition, including serious intercurrent illness, active hepatitis B or C or human immunodeficiency virus (HIV) infection, cirrhosis, > stage 3 liver fibrosis, INR >1.5, platelet count < 60.0x10^3/µL, significant cardiac disease (e.g. pulmonary artery pressure > 40 mm Hg, moderate or severe valvular dysfunction, or < 40% left ventricular ejection fraction by echocardiography (ECHO)), or any other extenuating circumstances that may significantly interfere with study compliance including all prescribed evaluations and follow-up activities;

• Has had a major organ transplant (e.g. bone marrow or liver);

• Has had a total splenectomy;

• Has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >250 IU/L or a total bilirubin >3.6 mg/dL;

• Is unwilling or unable to avoid the use of alcohol, medications that may decrease rhASM activity, medications or herbal supplements that may cause or prolong bleeding, and the use of medications or herbal supplements with potential hepatoxicity within 14 days prior to and 28 days afte the rhASM infusion.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acid Sphingomyelinase Deficiency
• Aphasia, Primary Progressive
• Frontotemporal Dementia
• Niemann-Pick Disease
• Niemann-Pick Disease, Type C
• Niemann-Pick Diseases
• Pick Disease of the Brain

Intervention

Drug:
• rhASM
Single dose of 0.03mg/kg body weight IV
• rhASM
Single dose of 0.1mg/kg body weight IV
• rhASM
Single dose of 0.3mg/kg body weight IV
• rhASM
Single dose of 0.6mg/kg body weight IV
• rhASM
Single dose of 1.0mg/kg body weight IV

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety assessments via physical exam,AE reporting,telemetry heartrate monitoring,ECG,ECHO,clinical lab evaluations,liver and adrenal function tests,cytokine testing,adrenal hormone levels,lipid profile,chest Xrays,liver biopsies,MRI of internal		Pre-, During-, and Post-infusion (up to 72 hrs); 14 day and 28 day follow-up visit	Yes
Primary	Immune Response Measure		Pre-infusion and final visit (Day 28)	Yes
Secondary	PK measurements		Pre- and Post-infusion up to 72 hrs.	No

External Links

•   Niemann Pick Disease Information